Behavioural relaxation training is a simplified technique which may be useful for those individuals who are unable to grasp and benefit from traditional procedures. One such population is Huntington's Disease patients who, in addition to characteristic choreiform movements, which are exacerbated by increased arousal, also suffer from progressive cognitive deterioration. This study used a multiple-baseline design to explore potential use of behavioural relaxation training with two patients who showed advanced disease. Improvement on heart rate and a behavioural measure of relaxation was noted. Results are discussed with respect to treatment of choreiform symptoms and the use of the procedure with other cognitively handicapped populations.

Aims Heart failure (HF) is a common cause of mortality and (re)hospitalisations. The NWE-Chance project explored the feasibility of providing hospitalisations at home (HH) supported by a newly developed digital health platform. The aim of this study was to explore the perceived usability by healthcare professionals (HCPs) of a digital platform in addition to HH for HF patients. Methods and results A prospective, international, multicentre, single-arm interventional study was conducted. Sixty-three patients and 22 HCPs participated. HH consisted of daily home visits by the nurse and use of the platform, consisting of a portable blood pressure device, weight scale, pulse oximeter, a wearable chest patch to measure vital signs (heart rate, respiratory rate, activity level and posture), and an eCoach for the patient. Primary outcome was usability of the platform measured by the System Usability Scale (SUS) halfway and at the end of the study. Overall usability was rated as sufficient (Mean score 72.1±8.9) and did not differ between the measurements moments (p=.690). HCPs reported positive experiences (n=7), negative experiences (n=13) and recommendations (n=6) for the future. Actual use of the platform was 79% of the HH days. Conclusion A digital health platform to support HH was considered usable by HCPs, although actual use of the platform was limited. Therefore, several improvements in the integration of the digital platform into clinical workflows and in defining the precise role of the digital platform and its use are needed to add value before full implementation. Registration ClinicalTrials.gov NCT04084964